Product Description: Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) is an orally active, highly selective antagonist of endothelin A receptors.
Applications: COVID-19-immunoregulation
Formula: C18H14ClN2NaO6S2
References: [1]Hartman JC, et al. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. Can J Physiol Pharmacol. 2010 Jun;88/[2]Tilton RG, et al. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist. Pulm Pharmacol Ther. 2000;13(2):87-97./[3]Rondelet B, et al. Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2010 Oct;299(4):H1118-23. Epub 2010 Aug 6.
CAS Number: 210421-74-2
Molecular Weight: 476.89
Compound Purity: 98.83
Research Area: Cardiovascular Disease; Endocrinology
Solubility: DMSO : 100 mg/mL (ultrasonic)/H2O : 100 mg/mL (ultrasonic)
Target: Endothelin Receptor
Deutsch
English
